13 January 2025
Futura Medical
plc
("Futura" or the
"Company")
Remuneration of Non-Executive
Directors and Total Voting Rights
Futura Medical plc (AIM: FUM) (the "Company"),
a pharmaceutical company developing a portfolio of innovative
products for sexual health and pain relief, announces the issue of 126,116 new ordinary shares of 0.2 pence each
("Ordinary Shares") in respect of the 2024 remuneration of its
Non-Executive Directors .
Remuneration of Non-Executive Directors
In accordance with the terms of
their service agreements, the Non-Executive Directors receive 25
per cent. of their remuneration in the form of Ordinary Shares. For
2024, these were issued at 27.10 pence per share, being the average
closing mid-market price of the last 10 trading days of 2023 (as
announced via RNS on 17 January 2024).
The 126,116 new Ordinary Shares
shall rank pari passu with the existing issued Ordinary Shares of
the Company and have been issued as follows:
|
Director
|
Number of Ordinary Shares issued for 2024
remuneration
|
Total number of ordinary shares held
|
Percentage of the Company's resulting issued share
capital
|
|
Jeff Needham
|
55,600
|
83,561
|
0.01%
|
|
Andrew Unitt
|
30,221
|
68,717
|
0.01%
|
|
Roy Davis
|
40,295
|
40,295
|
0.01%
|
|
|
|
|
|
The shares element of the
Non-Executive Directors' remuneration for 2025 will be awarded at
32.17 pence per Ordinary Share, being the average closing
mid-market price of the last 10 trading days of 2024. The
Non-Executive Directors will receive these shares in January
2026.
Total Voting Rights
Application has been made to the
London Stock Exchange and it is anticipated that trading of the new
Ordinary Shares will commence on AIM at 8:00am on 16 January
2025.
Immediately following the above
issue, the Company will have 303,829,684 ordinary shares in issue,
each carrying one voting right. Since the Company currently holds
no shares in treasury, the total number of voting rights in the
Company is therefore 303,829,684 and this figure may be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency
Rules.
Further details are contained within
the notifications below, made in accordance with Article 19 of the
EU Market Abuse Regulation 596/2014. Full
details of the Non-Executive Directors' remuneration will be
included in the Company's Annual Report & Accounts.
ENDS
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl, Will Goode, Mark Rogers
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Jeff Needham
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Director/ PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p
each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Issue of shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
27.10 pence
|
55,600
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
|
e)
|
Date of the transaction
|
16 January 2025
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Andrew Unitt
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Director/ PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p
each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Issue of shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
27.10 pence
|
30,221
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
|
e)
|
Date of the transaction
|
16 January 2025
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Roy Davis
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Director/ PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p
each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Issue of shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
27.10 pence
|
40,295
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
|
e)
|
Date of the transaction
|
16 January 2025
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
